Transplant Reports : Open Access
Open Access

Tissue engineering; Organ transplantation; Scaffold; Biomaterials; Stem cells; Bioreactors; Decellularization; 3D bioprinting; Regenerative medicine; Organ shortage

Introduction

Organ transplantation is often the only life-saving treatment for patients with end-stage organ failure. However, the severe shortage of suitable donor organs limits the availability of this therapy, resulting in long waiting lists and increased mortality [1]. Tissue engineering has emerged as a promising alternative approach to address this critical need by developing functional tissues and organs *in vitro* or *in vivo* [2]. This field combines principles from biology, engineering, and materials science to create biological substitutes that can restore, maintain, or improve damaged tissues or organs.

Description

This review summarizes current research on tissue engineering and its potential in organ transplantation. A comprehensive literature search was conducted using databases such as PubMed, MEDLINE, and Google Scholar, using keywords including "tissue engineering," "organ transplantation," "scaffold," "biomaterials," "stem cells," "bioreactors," "decellularization," "3D bioprinting," and related terms. Studies focusing on solid organ engineering and preclinical or clinical applications were prioritized.

Several key strategies are employed in tissue engineering for organ regeneration. One common approach involves using a scaffold, a three-dimensional structure that provides structural support and guidance for cell growth and tissue formation [3]. Scaffolds can be made from various biomaterials, including natural polymers such as collagen and hyaluronic acid, and synthetic polymers such as poly(lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL).

Stem cells, with their capacity for self-renewal and differentiation into various cell types, are another crucial component of tissue engineering [4]. Different types of stem cells, including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult stem cells, can be used to generate the specific cell types required for tissue regeneration.

Bioreactors, devices that provide a controlled environment for cell culture and tissue development, are also essential for engineering functional tissues and organs [5]. Bioreactors can provide mechanical stimulation, nutrient perfusion, and oxygenation, mimicking the physiological conditions required for tissue maturation.

Decellularization is a technique that involves removing cells from a native organ while preserving the extracellular matrix (ECM) scaffold [6]. This ECM scaffold can then be recellularized with recipient cells to create a bioengineered organ that is less likely to trigger an immune response.

3D bioprinting, a technology that uses layer-by-layer deposition of cells and biomaterials to create three-dimensional tissue constructs, has emerged as a powerful tool in tissue engineering [7]. This technique allows for precise control over tissue architecture and cell distribution, enabling the creation of complex tissue structures.

Discussion

Significant progress has been made in engineering various tissues and organs using these strategies. Skin, cartilage, and bone have been successfully engineered and are currently used in clinical applications. More complex organs, such as the liver, kidney, and heart, are the focus of intense research efforts.

Decellularized organ scaffolds have shown promise in preclinical studies. For example, decellularized lungs have been successfully recellularized and transplanted in animal models, demonstrating functional gas exchange [8].

3D bioprinting has been used to create functional tissue constructs, including vascularized tissues and organoids (miniature organ-like structures). These organoids can be used for drug screening, disease modeling, and potentially for transplantation in the future.

Despite these advancements, several challenges remain in translating tissue engineering from the laboratory to the clinic. Creating functional vascular networks within engineered tissues is crucial for providing oxygen and nutrients to cells and removing waste products. Achieving long-term functionality and integration of engineered tissues with the host is another significant challenge. Immunological rejection of engineered tissues remains a concern, although the use of recipient-derived cells or immunomodulatory strategies can help to mitigate this risk [9]. Scaling up production of engineered tissues and organs to meet clinical demand is also a major hurdle.

Ethical considerations surrounding the use of stem cells, particularly ESCs and iPSCs, need to be addressed. Regulations and guidelines for the clinical translation of tissue-engineered products are also needed.

Future research should focus on several key areas. Developing more sophisticated biomaterials that can better mimic the native ECM and promote cell-matrix interactions is crucial. Improving vascularization strategies and developing methods for creating functional microvascular networks within engineered tissues are essential. Further research is needed to optimize bioreactor design and culture conditions to promote tissue maturation and function. Developing strategies to induce immune tolerance to engineered tissues is also an important area of research. Combining different tissue engineering approaches, such as combining decellularization with 3D bioprinting, may offer synergistic benefits [10].

Conclusion

Tissue engineering holds tremendous potential to revolutionize organ transplantation by providing a solution to the critical organ shortage. Significant progress has been made in engineering various tissues and organs using different strategies. However, significant challenges remain in translating these advancements to clinical practice. Continued research and development in this field, focusing on improving vascularization, promoting tissue maturation, and addressing immunological concerns, are essential for realizing the full potential of tissue engineering in organ transplantation.

Acknowledgement

None

Conflict of Interest

None

References

1. Khosravi N, Pishavar E, Baradaran B, Oroojalian F, Mokhtarzadeh A, et al. (2022) Stem cell membrane, stem cell-derived exosomes and hybrid stem cell camouflaged nanoparticles: A promising biomimetic nanoplatforms for cancer theranostics. J Control Release 348:706-722.

Indexed at, Google Scholar, Crossref

2. Wu HH, Zhou Y, Tabata Y, Gao JQ (2019) Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic. J Control Release 28: 102-113.

Indexed at, Google Scholar, Crossref

3. Yan K, Zhang J, Yin W, Harding JN, Ma F et al. (2022) Transcriptomic heterogeneity of cultured ADSCs corresponds to embolic risk in the host. IScience 4: 104822.

Indexed at, Google Scholar, Crossref

4. Zhang W, Huang X (2022) Stem cell membrane-camouflaged targeted delivery system in tumor. Mater Today Bio 1: 100377.

Indexed at, Google Scholar, Crossref

5. Li Y, Wu H, Jiang X, Dong Y, Zheng J, et al. (2022) New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery. Acta Pharm Sin B 12: 3215-3232.

Indexed at, Google Scholar, Crossref

6. Ji B, Cai H, Yang Y, Peng F, Song M, et al. (2020) Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma. Acta Biomater 111: 363-372.

Indexed at, Google Scholar, Crossref

7. Wang M , Xin Y , Cao H , Li W , Hua Y, et al. (2021) Recent advances in mesenchymal stem cell membrane-coated nanoparticles for enhanced drug delivery. Biomater Sci 9:1088-1103.

Indexed at, Google Scholar, Crossref

8. Xia Q, Zhang Y, Li Z, Hou X, Feng N, et al. (2019) Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B 9: 675-689.

Indexed at, Google Scholar, Crossref

9. Shin MJ, Park JY, Lee DH, Khang D (2021) Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis. Int J Nanomedicine 16: 8485-8507.

Indexed at, Google Scholar, Crossref

10. Vasanthan V, Hassanabad AF, Fedak PWM (2021) Commentary: Cell therapy for spinal regeneration-implications for recovery after complex aortic surgery. JTCVS Open 24: 45-46.

Indexed at, Google Scholar, Crossref